Policy

A new science-focused autism committee mobilizes against controversial federal appointments.

Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.

Socioeconomic adversity in the perinatal period drives widening low birth weight gaps, fueling adverse pregnancy outcomes and deepening maternal and infant health inequities.

Nearly 3 million MA enrollees may lose plan coverage in 2026 as payment reforms drive market exits, hitting rural areas hardest and reshaping competition, explains Mark Meiselbach, PhD.

340B covered entities are expanding contracts with retail pharmacies that are increasingly located in counties with high rates of Medicare and Medicaid insurance coverage.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Kevin Ma, PhD, discusses new data showing 2024–2025 COVID-19 vaccines reduced hospitalization and severe outcomes.

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone.

Over 15,000 NYC nurses ratified new contracts after a 41-day strike, securing staffing protections, salary increases, and safety reforms.

MA grocery card use was associated with modest increases in wellness, primary care, and specialist visits among dual-eligible beneficiaries, says Jennifer L. Kowalski, MS.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health access and outcomes.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

A commentary by FDA officials Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH, details the new system for drug approvals in the US.

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes.

Medicare Advantage beneficiaries face forced disenrollment in 2026 as plan exits drive coverage termination, pushing millions toward traditional Medicare and Part D’s $2100 cap.

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

New bipartisan legislation extends key health care programs and tightens oversight of PBMs in Medicare Part D and commercial markets, but impacts on drug costs will not be immediate.

Penetration of Medicare Shared Savings Program accountable care organizations and Medicare Advantage was not associated with substantive changes in health care use among commercial enrollees.

These new data show that 64.8% of US adults take at least 1 prescription medication each year.